Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.53 - $35.25
Previous CloseN/A
Volume491.48K
Average Volume (3M)2.55M
Market Cap
$1.65B
Enterprise Value$739.40M
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$154.80M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Nov 10, 2025EPS Estimate
-1.03Last Dividend Ex-Date
Feb 04, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding101,162,025
10 Day Avg. Volume2,679,564
30 Day Avg. Volume2,552,585
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue12.27
Enterprise Value/Gross Profit332.62
Enterprise Value/Ebitda-1.86
Forecast
1Y Price Target
$42.67Price Target Upside130.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsBeam's base editing pipeline advances with ex vivo and in vivo programs poised to deliver first-in-class genetic medicines.
Competitive AdvantageBEAM-302 maintains a competitive edge in AATD after outperforming WVE-006 in critical metrics.
Financial PerformanceBeam Therapeutics shows strong financial health with approximately $1.15 billion in cash and a cash runway expected to extend into 2028.
Bears Say
Competitive PressureWave Life Science's WVE-006 lags behind BEAM-302 in key AATD treatment metrics, signaling competitive pressure.
Market FocusInvestor interest is primarily drawn to BEAM-302 in AATD, potentially overshadowing other Beam projects.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $13.53 and its highest was $35.25 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $1.65B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is in 66 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Aug 05, 2025. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.113 by $0.113.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics dividends here
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.03.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 101,162,025 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1 in its last earnings report, beating expectations of -$1.113. Following the earnings report the stock price went down -2.197%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.67 (130.15% Upside)
$42.67 (130.15% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 388.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $991.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.00%
12-Months-Change
Fundamentals
Return on Equity
-41.94%
Trailing 12-Months
Asset Growth
10.30%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM Stock 12 Month Forecast
Average Price Target
$42.67
▲(130.15% Upside)
Technical Analysis
Ownership Overview
1.59% Insiders
17.49% Mutual Funds
0.27% Other Institutional Investors
55.23% Public Companies and Individual Investors